Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-23 | Vivesto | Vivesto publicerar årsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-23 | Vivesto | Notice of Annual General Meeting in Vivesto AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-23 | Vivesto | Kallelse till årsstämma i Vivesto AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-19 | Vivesto | Vivesto to hold live-streamed Paccal Vet R&D Update on March 26 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-19 | Vivesto | Vivesto bjuder in till livesänd R&D Update med fokus på Paccal Vet den 26 mars | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-07 | Vivesto | Första patienten doserad i Vivestos kliniska studie med Paccal Vet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-07 | Vivesto | Vivesto doses first patient in its clinical Paccal Vet trial | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Vivesto doses first patient in its clinical Paccal Vet trialSolna, Sweden, March 7, 2024 – Vivesto AB, an oncology-focused development company, today announced that the first patient has been dosed in the company’s Paccal Vet open-label, pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy. An interim analysis is expected by the end of 2024. “It is great progress to have the first patient dosed in the Paccal Vet trial as this represents another important milestone towards demonstrating that Paccal Vet could be a suitable treatment option for dogs suffering from this severe cancer type where there are no approved drugs available. It is encouraging to see the great interest from study sites, and we anticipate that study enrollment will accelerate from now on,” said Erik Kinnman, CEO of Vivesto. The study will include four treatment cycles of Paccal Vet (paclitaxel micellar) and it is planned to investigate two cohorts. Each cohort is planned to include a maximum of 23 patients. The study will be conducted at six clinical sites in Washington and Oregon. If promising results in either cohort are shown, the study will be followed by a pivotal study designed to confirm the initial findings of this pilot study and to gather further evidence on the safety and efficacy of Paccal Vet in dogs with splenic hemangiosarcoma. Vivesto’s drug candidate Paccal Vet consists of paclitaxel formulated with the company’s proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness. Previous clinical studies performed by Vivesto has demonstrated safety in more than 300 dogs. Also, anti-tumor activity has been shown in squamous cell carcinoma and non-resectable mammary carcinoma of stage III-V. About hemangiosarcoma in dogs Treatment options for hemangiosarcoma include surgery and, for some of the dogs, an unapproved adjuvant chemotherapy. The median survival time for dogs with hemangiosarcoma of the spleen undergoing surgery alone is approximately 1-3 months, depending on the stage/seriousness of the disease. Chemotherapeutic agents are used to manage residual metastatic disease after surgery. The most common chemotherapy program in use today can extend survival with hemangiosarcoma of the spleen by 2-4 months. For more information: Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto. |
||||
2024-02-26 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Vivesto - Carnegie Investment Bank - 26 feb 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-22 | Vivesto | Bokslutskommuniké för räkenskapsåret 1 januari – 31 december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-01-30 | Vivesto | Vivestos internationella patentansökan för XR-18 får positivt besked | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-30 | Vivesto | Vivesto's international patent application for XR-18 receives positive decision | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-28 | Vivesto | Vivestos amerikanska kliniska studie med Paccal Vet får godkänt att starta patientrekrytering | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-28 | Vivesto | Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Vivesto | Vivesto’s Paccal Vet granted FDA MUMS designation | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Vivesto | Vivestos Paccal Vet beviljas MUMS-klassificering av FDA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Vivesto | Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Vivesto | Vivesto gör nedskrivning av tillgångar efter tillbakadragande av de europeiska marknadsföringstillstånden för Apealea | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-19 | Vivesto | Vivesto rapporterar positiva prekliniska data som stödjer fortsatt utveckling av Cantrixil | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-19 | Vivesto | Vivesto reports positive preclinical data supporting continued development of Cantrixil | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Vivesto | Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Vivesto | Valberedning utsedd inför Vivestos årsstämma 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Vivesto | Vivesto and Elevar sign agreement ending Apealea® partnership | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Vivesto | Vivesto och Elevar tecknar avtal för att avsluta partnerskap rörande Apealea® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-17 | Penser Access | Penser Access: Intervju med Vivesto - Erik Penser Bank - 17 november 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Vivesto | Delårsrapport för perioden 1 januari – 30 september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-16 | Vivesto | Interim report for the period January 1, 2023 – September 30, 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Penser Access | Penser Access: Intervju med Vivesto - Erik Penser Bank - 26 oktober 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-10-25 | Vivesto | Vivesto fokuserar projektportföljen och inför kostnadsbesparande åtgärder | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-25 | Vivesto | Vivesto focuses its project portfolio and introduces cost-saving measures | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-15 | Vivesto | Avnotering av Vivestos aktier från Frankfurt Stock Exchange per den 15 september 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-15 | Vivesto | Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | Vivesto | Interim report for the period January 1, 2023 – June 30, 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | Vivesto | Delårsrapport för perioden 1 januari – 30 juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-04 | Vivesto | Vivesto announces early termination of patient enrollment in the investigator-initiated Phase 1b Docetaxel micellar study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-04 | Vivesto | Vivesto meddelar att rekryteringen av patienter i den prövarinitierade fas 1b-studien med Docetaxel micellar avslutas i förtid | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-16 | Vivesto | Vivesto har haft positivt pre-submission möte med FDA om Paccal Vet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-16 | Vivesto | Vivesto announces positive Paccal Vet FDA pre-submission meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Vivesto | Kommuniké från årsstämma i Vivesto AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Vivesto | Report from Annual General Meeting in Vivesto AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Vivesto | Delårsrapport för perioden januari – mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Vivesto | Interim report for the period January 2023 – March 2023 | Rapporter | Ladda ner | Visa Stäng |
|